ESMO 2018 | Denosumab for NSCLC: results from SPLENDOUR

Solange Peters

Speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Solange Peters, MD, PhD, of University Hospital Vaudois, Lausanne, Switzerland, gives us an update on the ETOP and EORTC SPLENDOUR trial (NCT02129699) of denosumab for advanced non-small cell lung cancer.

Share this video  
Similar topics
Related videos
0:48
The LUNAR study: TTFields for NSCLC
Ori Farber
0:55
Tumor treating fields as an anti-mitotic therapy
Ori Farber
0:48
Patient impact: development of drugs to treat METex14 alterations
Paul Paik
1:04
Tepotinib: advanced non-small cell lung cancer
Paul Paik
0:53
Future treatment options for squamous cell lung cancer
Paul Paik
Lung Cancer, Non-Small Cell Lung Cancer
Denosumab
SPLENDOUR
ESMO 2018
Interview
19th October 2018
More from Solange Peters
Exciting current topics in lung cancer
Challenges and opportunities for patients with advanced NSCLC
Results from the PACIFIC study: durvalumab with chemoradiation for the treatment of NSCLC
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals